165 related articles for article (PubMed ID: 8813462)
1. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo.
Weckbecker G; Raulf F; Tolcsvai L; Bruns C
Digestion; 1996; 57 Suppl 1():22-8. PubMed ID: 8813462
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
3. Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Viale M; Pastrone I; Pellecchia C; Vannozzi MO; Cafaggi S; Esposito M
Anticancer Drugs; 1998 Jun; 9(5):457-63. PubMed ID: 9660544
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
5. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
6. ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Georgieva I; Koychev D; Wang Y; Holstein J; Hopfenmüller W; Zeitz M; Grabowski P
Neuroendocrinology; 2010; 91(2):121-30. PubMed ID: 19923785
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor effects of chemotherapeutic drugs on human gastric cancer cells in vitro and the relationship with expression of hTERT mRNA].
Geng M; Yin YC; Cao YC; Fu ZJ; Wang XY; Tai YH
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):838-41. PubMed ID: 18396642
[TBL] [Abstract][Full Text] [Related]
8. [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma].
Liu CL; Tang CW; Zhou XC
Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):313-5. PubMed ID: 12882711
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Holmes FA
Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro.
Weckbecker G; Liu R; Tolcsvai L; Bruns C
Cancer Res; 1992 Sep; 52(18):4973-8. PubMed ID: 1325289
[TBL] [Abstract][Full Text] [Related]
11. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
Jia WD; Xu GL; Xu RN; Sun HC; Wang L; Yu JH; Wang J; Li JS; Zhai ZM; Xue Q
J Cancer Res Clin Oncol; 2003 Jun; 129(6):327-34. PubMed ID: 12811549
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo.
Hoelting T; Duh QY; Clark OH; Herfarth C
J Clin Endocrinol Metab; 1996 Jul; 81(7):2638-41. PubMed ID: 8675590
[TBL] [Abstract][Full Text] [Related]
13. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
Zhang Y; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Jan; 33(2):679-91. PubMed ID: 22019123
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.
Shurin GV; Tourkova IL; Kaneno R; Shurin MR
J Immunol; 2009 Jul; 183(1):137-44. PubMed ID: 19535620
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
[TBL] [Abstract][Full Text] [Related]
19. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
